SCHEDULE: ARK Investment Management Discloses CRISPR Therapeutics Stake

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting beneficial ownership of 11.79% of CRISPR Therapeutics AG's common stock as of March 31, 2026.

Summary

• ARK Investment Management LLC and Catherine D. Wood have jointly filed an amendment (Amendment No. 13) to their Schedule 13G filing.
• The filing pertains to their beneficial ownership of the Common Stock of CRISPR Therapeutics AG.
• As of March 31, 2026, the aggregate amount beneficially owned by ARK Investment Management LLC and Catherine D. Wood is 11,313,623 shares.
• This represents 11.79% of the class of securities.
• ARK Investment Management LLC holds sole voting power over 10,545,920 shares and shared voting power over 208,180 shares.
• Catherine D. Wood holds shared voting power over 10,754,100 shares.
• ARK Investment Management LLC has sole dispositive power over 11,313,623 shares.
• Catherine D. Wood has shared dispositive power over 11,313,623 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of ownership and does not contain new operational or financial performance information.

Positives

• ARK Investment Management LLC and Catherine D. Wood maintain a significant beneficial ownership stake of 11.79% in CRISPR Therapeutics AG.
• The filing indicates that the securities are held in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Risks

• While not explicitly stated as a risk in this filing, significant ownership by an investment firm can sometimes lead to increased scrutiny or pressure on management regarding strategic decisions or performance.

Future Outlook

This filing is primarily a disclosure of ownership and does not contain forward-looking statements or guidance regarding CRISPR Therapeutics AG's future performance.

Management Comments

• "ARK Investment Management LLC and Catherine D. Wood do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file an Amendment No. 13 on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Amendment No. 13 on Schedule 13G shall be filed on behalf of each of them."
• Certification: "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by ARK Investment Management, known for its focus on disruptive innovation, indicates continued significant investment in the gene editing and biotechnology sector, specifically in CRISPR Therapeutics AG, a key player in this rapidly evolving field.

Stakeholder Impact

• Shareholders: The significant stake held by ARK may influence market perception and potentially impact share price due to ARK's investment strategy and reputation.
• Management: The substantial ownership by ARK could lead to increased engagement or dialogue with the company's management regarding strategic direction.

Next Steps

• Continued monitoring of ARK Investment Management's ownership levels and any future amendments to the Schedule 13G filing.

Key Dates

Keywords

CRISPR Therapeutics AG, Schedule 13G, ARK Investment Management LLC, Catherine D. Wood, Beneficial Ownership, Common Stock, SEC Filing, Amendment, Investment Management